Atara Biotherapeutics, headquartered in Thousand Oaks, California, is a biotechnology company specializing in allogeneic T-cell immunotherapy, with products like Ebvallo and ATA3219 in various development stages. The company went public on October 16, 2014, and employs 173 staff.
ATRA has been in the news recently: Atara Biotherapeutics has raised $36 million by selling shares and pre-funded warrants, with shares priced at $8.25 each. The company will present its T-cell immunotherapy innovations at the H.C. Wainwright Conference on September 9, 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
